Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Abstract BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a...

Full description

Bibliographic Details
Main Authors: Elio Novembre, Mariangela Tosca, Carlo Caffarelli, Mauro Calvani, Fabio Cardinale, Riccardo Castagnoli, Elena Chiappini, Claudio Cravidi, Michele Miraglia Del Giudice, Marzia Duse, Amelia Licari, Sara Manti, Alberto Martelli, Giampaolo Ricci, Giuseppe Pingitore, Gian Luigi Marseglia
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Italian Journal of Pediatrics
Subjects:
COVID-19
SARS-CoV-2
Vaccine
Children
Adverse event
Allergy
Online Access:https://doi.org/10.1186/s13052-022-01272-z

Similar Items

Similar Items